Keryx shares jump on media report

April 12 (Reuters) - Shares of Keryx Biopharmaceuticals Inc rose to their highest in two years Monday, a day after a media report said the stock could triple in value over the next year.

Brean Murray Carret and Co analyst Jonathan Aschoff pointed to a report Sunday on the Seeking Alpha website that suggests that Keryx's stock could reach $14 by 2011.

Keryx shares, which have gained about 30 percent in the last one month, were up 21 percent at $4.20 Monday afternoon. They touched a high of $4.22 earlier in the day.

On April 5, Keryx stock gained as much as 22 percent as its experimental cancer drug perifosine received fast-track status from the U.S. health regulator.

The status grants the company and its Canadian partner Aeterna Zentaris seven years of market exclusivity.

(Reporting by Vidya L Nathan in Bangalore; Editing by Unnikrishnan Nair) Keywords: KERYXBIOPHARMACEUTICALS/SHARES ([e-mail]; within U.S. [phone]; outside U.S. [phone]; Reuters Messaging: [e-mail]) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.